Summary

Market Overview
The Global RNAi Technology Market was valued at USD 1.19 billion in 2024 and is projected to reach USD 2.14 billion by 2030, expanding at a CAGR of 10.28% during the forecast period. RNA interference (RNAi) has emerged as a transformative tool in the biotechnology and pharmaceutical sectors, enabling targeted gene silencing through small RNA molecules. This mechanism has reshaped the landscape of gene regulation and therapeutic innovation, finding applications across drug development, gene therapy, agriculture, and molecular research. With its ability to selectively inhibit disease-related genes, RNAi is increasingly being integrated into drug pipelines for treating complex conditions such as cancer, genetic disorders, and viral infections. Pharmaceutical companies are prioritizing RNAi-based approaches due to their high precision, adaptability, and potential for developing personalized treatments. The continuous advancements in delivery systems, coupled with growing investments in RNAi therapeutics and diagnostics, are expected to drive robust market expansion through 2030.
Key Market Drivers
Growing Demand for RNAi-based Therapeutics
The rising demand for RNAi-based therapeutics plays a critical role in propelling the growth of the global RNAi technology market. RNAi enables highly targeted treatment by silencing genes that contribute to the progression of chronic and genetic diseases, such as certain cancers, viral infections, and neurodegenerative conditions. As the global prevalence of such disorders continues to rise, there is a growing need for precise and less invasive treatment options. RNAi-based drugs support a personalized medicine approach, tailoring therapies based on individual genetic profiles and minimizing off-target effects. The successful commercialization of RNAi therapies, such as Onpattro, has strengthened confidence in the clinical viability of these treatments, encouraging more companies to invest in research and development. Furthermore, RNAi’s utility in functional genomics and target validation makes it a valuable tool in drug discovery, reinforcing its expanding role across both therapeutic and research domains.
Key Market Challenges
Off-Target Effects
Off-target gene silencing presents a major obstacle to the widespread adoption of RNAi technology. Although RNAi is known for its precision, unintended interactions with non-target genes can lead to undesired cellular responses, including toxicity or immune reactions. These safety concerns require extensive preclinical and clinical validation, increasing development time and costs. Designing RNAi molecules with high specificity remains a complex task, particularly when targeting genes in complex biological systems. Off-target effects not only compromise therapeutic outcomes but also affect research accuracy in functional genomics. Addressing this challenge involves improving RNA sequence design, refining delivery mechanisms, and enhancing regulatory oversight to ensure the safe application of RNAi in both clinical and research settings.
Key Market Trends
Precision Medicine and Personalized Therapies
The integration of RNAi technology into precision medicine is a significant trend shaping the future of the healthcare industry. As personalized therapies become increasingly important, RNAi's ability to silence specific genetic mutations makes it an ideal platform for individualized treatment strategies. In oncology, for instance, RNAi-based therapies are being developed to target genetic mutations unique to different tumor types, offering greater efficacy and reduced side effects compared to conventional therapies. This alignment with personalized medicine is also driving partnerships and R&D efforts focused on developing tailored RNAi-based solutions. By enabling gene-specific modulation, RNAi supports the broader shift toward customized, data-driven healthcare approaches.
Key Market Players
• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis S.A.
Report Scope:
In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• RNAi Technology Market, By Type:
o Micro RNA
o Small interfering RNA
o Others
• RNAi Technology Market, By Application:
o Treatment Type
o Therapeutics
o Drug Delivery
o Agriculture
o Others
• RNAi Technology Market, By End User:
o Research and Academic Laboratories
o Diagnostic Laboratories
o Others
• RNAi Technology Market, By Region:
o North America
 § United States
 § Canada
 § Mexico
o Europe
 § France
 § United Kingdom
 § Italy
 § Germany
 § Spain
o Asia-Pacific
 § China
 § India
 § Japan
 § Australia
 § South Korea
o South America
 § Brazil
 § Argentina
 § Colombia
o Middle East & Africa
 § South Africa
 § Saudi Arabia
 § UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.
Available Customizations:
Global RNAi Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global RNAi Technology Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
5.2.4. By Company (2024)
5.2.5. By Region
5.3. Market Map
6. North America RNAi Technology Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States RNAi Technology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Mexico RNAi Technology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Canada RNAi Technology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. Europe RNAi Technology Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France RNAi Technology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. Germany RNAi Technology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom RNAi Technology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy RNAi Technology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain RNAi Technology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. Asia-Pacific RNAi Technology Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China RNAi Technology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India RNAi Technology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. South Korea RNAi Technology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. Japan RNAi Technology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia RNAi Technology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. South America RNAi Technology Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil RNAi Technology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina RNAi Technology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia RNAi Technology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. Middle East and Africa RNAi Technology Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa RNAi Technology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia RNAi Technology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. UAE RNAi Technology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global RNAi Technology Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Alnylam Pharmaceuticals, Inc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed)
15.1.5. Recent Developments
15.1.6. Key Personnel Details

15.1.7. SWOT Analysis
15.2. Ionis Pharmaceuticals, Inc.
15.3. Atalanta Therapeutics
15.4. Phio Pharmaceuticals
15.5. Benitec Biopharma
15.6. Novartis AG
15.7. AstraZeneca
15.8. Silence Therapeutics
15.9. Arbutus Biopharma
15.10. Sylentis S.A.
16. Strategic Recommendations
17. About Us & Disclaimer